Discovery and Optimization of Tambjamines As a Novel Class of Antileishmanial Agents.

Published In

Journal of Medicinal Chemistry

Document Type

Citation

Publication Date

5-9-2024

Abstract

Leishmaniasis is a neglected tropical disease that is estimated to afflict over 12 million people. Current drugs for leishmaniasis suffer from serious deficiencies, including toxicity, high cost, modest efficacy, primarily parenteral delivery, and emergence of widespread resistance. We have discovered and developed a natural product-inspired tambjamine chemotype, known to be effective against spp, as a novel class of antileishmanial agents. Herein, we report in vitro and in vivo antileishmanial activities, detailed structure-activity relationships, and metabolic/pharmacokinetic profiles of a large library of tambjamines. A number of tambjamines exhibited excellent potency against both and parasites with good safety and metabolic profiles. Notably, tambjamine offered excellent potency and provided partial protection to leishmania-infected mice at 40 and/or 60 mg/kg/10 days of oral treatment. This study presents the first account of antileishmanial activity in the tambjamine family and paves the way for the generation of new oral antileishmanial drugs.

Rights

© 2024 American Chemical Society

DOI

10.1021/acs.jmedchem.4c00517

Persistent Identifier

https://archives.pdx.edu/ds/psu/41822

Share

COinS